10th Anniversary of Biomedicines—Pathogenesis and Innovative Therapies in Ovarian Cancer

Dear Colleagues,

The year 2023 marks the 10th anniversary of Biomedicines, a peer-reviewed open access journal in the biomedical field. So far, Biomedicines has published more than 2700 papers from more than 17,000 authors. We appreciate each author, reviewer, and academic editor whose support has brought us to where we are today.

To celebrate this significant milestone, we aim to publish a Special Issue titled “10th Anniversary of Biomedicines—Pathogenesis and Innovative Therapies in Ovarian Cancer (OC)”. OC is the most lethal gynecological disease and is characterized by heterogeneity, a high risk of relapse and the development of chemoresistance; thus, resulting in poor prognosis. Genetic and epigenetic factors and microenvironment characteristics influence the progression of the disease and its response to therapy.  To date, the cornerstone of treatment has been maximal-effort surgical cytoreduction combined with cytotoxic chemotherapy, mainly represented by combinations of carboplatin and paclitaxel, both in adjuvant and metastatic settings.  An estimated 80–85% of patients with OC who achieve full remission following first-line platinum-based therapy will develop disease recurrence, and the median survival for these patients ranges from 12 months to 24 months. Except for bevacizumab and poly ADP-ribose polymerase inhibitors, there are few other options for women with platinum-resistant OC. It is, therefore, particularly important to deepen the pathobiology of the tumor itself, and further understand how it is influenced by the microenvironment and by the genetic heterogeneity present not only in cancer from different patients, but also within a single cancer. A greater understanding of all these factors could be very useful in the development of more personalized therapies that maintain activity against resistant cells and take into account the specific characteristics of each individual tumor.

Dr. Francesca Magherini
Dr. Tania Gamberi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.